Market Research Report
United States Liquid Biopsy Growth Opportunities
|United States Liquid Biopsy Growth Opportunities|
Published: February 22, 2022
Frost & Sullivan
Content info: 73 Pages
Delivery time: 1-2 business days
Non-invasive Liquid Biopsy Technology Shapes the Precision Diagnostics Landscape
Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio.
Advances in next-generation sequencing-based companion diagnostics (CDx) and liquid biopsy (LBx) enable precision medicine approaches toward diseases such as cancer. Another aspect changing the diagnostics industry is linking automation to digital technologies to improve efficiency and productivity. This includes leveraging artificial intelligence to enhance workflow and accuracy.
Frost & Sullivan's analysis shows that the top 5 companies in the US liquid biopsy market-Exact Sciences, Guardant Health, Roche/Foundation Medicine, Natera, and LabCorp-account for 77.5% of its revenue in 2020. We expect the market to reach $7.02 billion by 2025 at a 14% CAGR.
The report provides updates on the competitive landscape by analyzing market dynamics, participants, and investments. It also offers stakeholders insights through forecasts, analysis by therapy (oncology and non-oncology) and product type (kits and reagents, instruments and analysis platforms, testing and development services), and growth opportunities.